Skip to main content

From the helm: Proteomics International (ASX:PIQ), Dr. Richard Lipscombe, Managing Director

Bell Direct
July 7, 2025

In this episode of From the helm, Bell Financial Group’s Grady Wulff speaks with Proteomics International Laboratories (ASX: PIQ) CEO, Dr. Richard Lipscombe, about the company’s ground breaking work in predictive diagnostics and the global opportunity for its world-first blood tests.

In this video, Dr. Lipscombe covers:
·      (0:47): An overview of PIQ and its FY26 goals
·      (1:38): The significance of three world-first blood tests
·      (5:26): The global addressable markets for these conditions
·      (6:25): Clinical trial progress and commercialisation roadmap
·      (8:14): How the diagnostic tests work and deliver value to patients
·      (9:16): Commercialisation strategy across key regions
·      (11:23): Additional assets in the PIQ pipeline
·      (12:36): What investors can expect over the next 12 months

Note: This interview was recorded on 3 July 2025.

Weekly Wrap 23 June

Grady Wulff
June 23, 2023

Morning Bell 23 June

Sophia Mavridis
June 23, 2023

Morning Bell 22 June

Sophia Mavridis
June 22, 2023

Morning Bell 21 June

Grady Wulff
June 21, 2023

Morning Bell 20 June

Grady Wulff
June 20, 2023

Morning Bell 19 June

Grady Wulff
June 19, 2023

Weekly Wrap 16 June

Grady Wulff
June 16, 2023

Morning Bell 15 June

Grady Wulff
June 15, 2023

Morning Bell 14 June

Grady Wulff
June 14, 2023

Morning Bell 13 June

Sophia Mavridis
June 13, 2023

Weekly Wrap 9 June

Sophia Mavridis
June 9, 2023

Morning Bell 8 June

Grady Wulff
June 8, 2023